Insights from
UBC's Expert Voices

The first oncology JCA reports show that this new EU assessment process is anything but routine. Here's what sponsors can learn from early submissions, and how to prepare for what's ahead.

The question for Patient Services leaders isn't automation vs. AI. It's knowing where each capability creates value, where it introduces risk, and how to build both into a stronger service model.

The story of patient access this year is really two stories that meet in the same place. The first is structural: the insurance landscape is being rebuilt, reshaping how pharmacy benefits are paid for, how long people keep coverage, and what a marketplace plan covers. The second is where patients feel it.

With immature survival data, single-arm trials, and limited comparators common in early JCA submissions, real-world evidence is becoming a strategic necessity, not an afterthought. Learn how sponsors can plan and generate RWE that meets the methodological bar EU assessors expect.

The EU Joint Clinical Assessment is driving a new approach to evidence generation, where regulatory approval and market access considerations must be addressed together. Drawing on lessons from the first completed and discontinued JCA cases, this article explores how integrated evidence planning, comparative effectiveness evidence, proactive PICO management, and strategic use of real-world evidence can help organizations navigate evolving European requirements and support successful reimbursement and patient access outcomes.

AI can support much more than drafting content. In Part 2 of our series, we explore practical tools that help teams organize information, improve communication, capture meeting insights, visualize complex concepts, and work more efficiently so experts can stay focused on what matters most.

A 95% compliance rate sounds strong, until you calculate what it means at 100,000 cases a year. Here's what's actually hiding in that gap, and the four questions every sponsor should ask before signing with a PV vendor.

AI isn't replacing pharmacovigilance professionals. It's changing how they work. Learn why the centaur model, where humans direct AI rather than defer to it, is emerging as the standard for regulated safety operations.

AI savings numbers are easy to put in a proposal. What's harder to find is what happens when something goes wrong. Here's a framework for pricing in the risk that vendor pitches leave out, plus four questions worth asking before you switch.